Systane ilux2

Tap to find out more
And see how the full range of
Systane® iLux2® can bring your practice
to the forefront of MGD treatments

IMPORTANT PRODUCT INFORMATION

Indication: The Systane® iLux2® is indicated for the application of localized heat and pressure therapy in adult patients with meibomian gland dysfunction (MGD), which is associated with evaporative dry eye, and to capture/store digital images and video of the meibomian glands.

Contraindications:

Do NOT use the Systane® iLux2® in patients with the following conditions: Patients whose pupils have been pharmaceutically dilated; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior 3 months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.

Warnings/Precautions:

Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.

The Disposable may not fit all eyes, such as eyes with small palpebral fornices. Use of the Systane® iLux2® is NOT recommended in patients with the following conditions: moderate to severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; patients with punctal plugs, or patients who have undergone ocular surgery within prior 3 months.

Potential Adverse Reactions:

Potential adverse effects may occur because of the procedure. These effects include but are not limited to, the onset or increase in: eyelid/eye pain requiring discontinuation of the treatment procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctival edema or conjunctival injection (hyperemia)), and ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).

Attention: Please refer to the User Manual for a complete list of contraindications, instructions for use, warnings and precautions for the Systane® iLux2®.

References:
1. MarketScope LLC. 2020 Dry Eye Products Report: A Global Market Analysis for 2019 to 2025. St. Louis, MO: MarketScope LLC; 2020.

2. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31:472-478.

3. TFOS. TFOS DEWS II. Available at http://www.tearfilm.org/dettreports-tfos dew_ii_report/32_30/eng/. Accessed May 9, 2018.

4. Market Scope. 2018 Dry eye products report: a global market analysis for 2017 to 2023. Saint Louis, MO: Market Scope; November 2018.

5. Alcon data on file, 2018.

6. The Dry Eye Problem. Building Your Dry Eye Center of Excellence. Review of Optometric Business supplement. https://www.reviewob.com/building-your-dry-eye-center-of-excellence/. Accessed July 13, 2021.

7. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea. 2011;30(4):379-387.

8. Tomlinson A, Bron AJ, Korb DR, et al. The International Workshop on Meibomian Gland Dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci. 2011;52:2006-204.

9. Cochener B, Cassan A, Omiel L. Prevalence of meibomian gland dysfunction at the time of cataract surgery. J Cataract Refract Surg. 2018;44(2):144-148. doi:10.1016/j.jcrs.2017.10.050.

10. Viso E, Rodrfguez-Ares MT, Abelenda D, Oubifia B, Gude F. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci. 2012;53(6):2601-2606.

11. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412-1419.

12. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593-603.